Rathbones Group PLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 22.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 136,437 shares of the company's stock after purchasing an additional 25,256 shares during the quarter. Rathbones Group PLC owned approximately 0.17% of IDEXX Laboratories worth $56,409,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at about $29,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth $30,000. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories during the 4th quarter worth $31,000. Kestra Investment Management LLC bought a new position in IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Crews Bank & Trust acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $41,000. Institutional investors and hedge funds own 87.84% of the company's stock.
Insiders Place Their Bets
In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.
IDEXX Laboratories Stock Up 2.4 %
Shares of IDXX stock traded up $9.11 during trading hours on Friday, hitting $390.94. 1,329,119 shares of the company were exchanged, compared to its average volume of 616,387. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The business has a 50 day moving average of $428.03 and a two-hundred day moving average of $434.13. The company has a market capitalization of $31.68 billion, a PE ratio of 36.64, a PEG ratio of 3.41 and a beta of 1.50.
Analyst Ratings Changes
Several research firms recently issued reports on IDXX. Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research report on Wednesday, January 29th. Finally, StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Four investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $533.75.
View Our Latest Analysis on IDXX
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Articles
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
